• Biomolecules & Therapeutics
• /
• 제6권4호
• /
• pp.412-416
• /
• 1998

Acute oral toxicity of Bifidobacterium breve K-110, Bifidobacterium breve K-111, Bifidobacterium infantis K-525 were studied in Sprague-Dawley rats of both sexes. In this study, we examined number of deaths, clinical signs, bod weight and gross findings for 14 day after single oral administration of B. breve K-110,B. breve K-111 or B. infantis K-525 with different levels. They did not show any toxic effect in rats and oral LD$_{50}$ value was over 5 g/kg in rats.s.

• 한국식품과학회지
• /
• 제31권2호
• /
• pp.547-552
• /
• 1999

저자 등이 건강한 한국사람으로부터 장내유해효소를 억제할 수 있은 장내환경개선효과가 우수한 한국형 유산균을 분리하여 소장수송능 효과, castor oil을 이용한 설사모델 동물에서 지사효과 및 항돌연변이 효과를 측정한 결과 소장의 수송능에는 아무런 영향을 미치지 못했으나 대장의 소송능은 현저한 수송능 촉진효과를 나타냈으며 특히 Bifidobacterium breve K-110의 균주가 우수하였다. Castor oil로 유도된 설사에 대한 지사 효과는 대부분의 균주에서 억제효과가 인정되지 않았으나, K-111의 균주는 유의한 지사효과를 나타냈다. 아울러 유산균은 항돌연변이 효과는 Bifidobacterium breve K-100 균주가 가장 우수한 효과를 나타내었으며 이러한 효과는 유산균의 세포벽 성분이 peptidoglycan에 의한 효과였다. 이러한 결과들로 볼 때 한국형유산균은 장내세균이 생산하는 유해효소의 생산성을 억제하는 것외에도 설사와 변비를 개선할 수 있으며 발암물질에 의한 항돌연변이 효과을 통해서 장내환경개선 효과를 기대할 수 있을 것으로 생각된다.

• 약학회지
• /
• 제42권6호
• /
• pp.639-641
• /
• 1998

Minimal inhibitory concentrations (MICs) of Bifidobacterium spp. strains (Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525) isolated from healthy Korean against antituberculosis agents and fluoroquinolones were determined. From the MICs it was found that Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525 were susceptible to rifampicin and fluoroquinolenes and resistant to other antituberculosis agents.

• 한국식품과학회지
• /
• 제31권4호
• /
• pp.1096-1100
• /
• 1999

The protective effect of Bifidobacterium breve K-110, K-111 and B. infantis K-525 on carbon tetrachloride induced hepatotoxicity in rats was investigated. Among them, B. infantis K-525 had the most potent hepatoprotective activity. It reduced serum aspartate aminotransferase and alanine aminotransferase levels to 51% and 80% of the $CCl_{4}-treated$ groups, respectively. In rat liver homogenate intoxificated with $CCl_{4}$, B. infantis K-525 inhibited in vitro as well as in vivo lipid peroxidation more than the other Bifidobacteria.

• Journal of Microbiology and Biotechnology
• /
• 제9권3호
• /
• pp.368-370
• /
• 1999

The protective role of Bifidobacterium spp. (B. breve K-110, B. breve K-111, and B. infantis K-525) isolated from the fecal samples of healthy Koreans was investigated on 1,2-dimethylhydrazine (DMH)-induced aberrant crypt foci(ACF) formation in mouse colon. In mice fed normal diet with DMH treatment, an average of 68.5 ACF/colon was formed, whereas in mice administered with B. breve K-110, B. breve K-111, and B. infantis K-525, the numbers of DMH-induced ACF decreased to 7.2, 10.9, and 6.6 ACF/ colon, respectively. The mean number of crypts/focus was not significantly altered. Fecal harmful enzymes, such as β-glucuronidase, tryptophanase, and urease, were effectively inhibited during the administration of these bifidobacteria to mice. These results suggest that bifidobacteria could prevent colon cancer.

• Journal of Microbiology and Biotechnology
• /
• 제12권4호
• /
• pp.553-556
• /
• 2002

The inhibitory activity of fifty Bifidobacteria toward the infectivity of a rotavirus, which is the predominant cause of sporadic diarrhea in infants and young children, was investigated, and Bifidobacterium breve K-110 was found to have the most potent inhibitory activity. Accordingly, the rotavirus infection-inhibitory protein was purified, and its molecular weight was determined to be 76 kDa by SDS-PAGE. It was heat-labile and its 50% inhibitory concentration ($IC_{50}$) was 0.045 $\mu g/ml$.

• Archives of Pharmacal Research
• /
• 제25권5호
• /
• pp.681-684
• /
• 2002

This study was undertaken to investigate the hypocholesterolemic activity of Bifidobacteria (B. breve K-110, B. breve K-111, and B. infantis K-525) isolated from a healthy Korean. The administration of B. breve K-110 and K-111 with a high cholesterol diet significantly protected the increase of serum total cholesterol and LDL cholesterol relative to that of a high cholesterol diet alone. Such a diet supplemented with 0.5％ B. breve K-111 decreased serum total cholesterol and LDL cholesterol to 57 and 55％, respectively. The administration of Bifidobacteria also significantly inhibited the lipid-deposited surface in the aorta. The normalizing activity of serum cholesterol level in cholesterolemic rats was accelerated by Bifidobacteria. The normalizing activity of B. breve K-111 on serum cholesterol level was superior to that of B. breve K-110. These results suggest that Bifidobacteria in the human intestine playa role in the prophylactics of arteriosclerosis.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.333.2-333.2
• /
• 2002

Kakkalide from Puerariae Flos expresses pharmacological actions after biotransformation to irisolidone by intestinal bacteria. B. breve K-110 was isolated as a bacterium metabolizing kakkalide. Therefore. we purified kakkalide-metabolizing p-Xylosidase from B. breve K-110. ${\beta}$-Xylosidase from B. breve K-110 (isolated from Korean intestinal microflora) was induced by kakkalide. We used defined medium contating 1mM kakkalide for the cultivationof B. breve K-110. (omitted)

• Journal of Microbiology and Biotechnology
• /
• 제22권4호
• /
• pp.535-540
• /
• 2012

${\beta}$-D-Xylosidase (E.C. 3.2.1.37) from Bifidobacterium breve K-110, which hydrolyzes ginsenoside Ra1 to ginsenoside Rb2, was cloned and expressed in Escherichia coli. The ($His_6$)-tagged recombinant enzyme, designated as XlyBK-110, was efficiently purified using $Ni^{2+}$-affinity chromatography (109.9-fold, 84% yield). The molecular mass of XylBK-100 was found to be 55.7 kDa by SDS-PAGE. Its sequence revealed a 1,347 bp open reading frame (ORF) encoding a protein containing 448 amino acids, which showed 82% identity (DNA) to the previously reported glycosyl hydrolase family 30 of Bifidobacterium adolescentis ATCC 15703. The $K_m$ and $V_{max}$ values toward p-nitrophenyl-${\beta}$-D-xylopyranoside (pNPX) were 1.45mM and 10.75 ${\mu}mol/min/mg$, respectively. This enzyme had pH and temperature optima at 6.0 and $45^{\circ}C$, respectively. XylBK-110 acted to the greatest extent on xyloglucosyl kakkalide, followed by pNPX and ginsenoside Ra1, but did not act on p-nitrophenyl-${\alpha}$-L-arabinofuranoside, p-nitrophenyl-${\beta}$-D-glucopyranoside, or p-nitrophenyl-${\beta}$-D-fucopyranoside. In conclusion, this is the first report on the cloning and expression of ${\beta}$-D-xylosidase-hydrolyzing ginsenoside Ra1 and kakkalide from human intestinal microflora.

• Archives of Pharmacal Research
• /
• 제21권1호
• /
• pp.54-61
• /
• 1998

Five hundreds of bifidobacteria were isolated from a healthy Korean and the inhibitory effects of these isloated bacteria on harmful enzymes of human intestinal microflora were examined by cocultivation of the isolated bifidobacteria with E. coli or total human intestinal microflora. In comparison with the results of E. coli or intestinal microflora cultivation, Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525 effectively inhibited harmful enzymes ($\beta$-glucuronidase and tryptophanase) of E. coli and lowered the pH of the culture media. Also they inhibited the harmful enzymes ($\beta$-glucosidase, $\beta$-glucuronidase, tryptophanase and urease) and ammonia production of intestinal microflora, and lowered pH of the culture media by increasing lactic acid bacteria of intestinal microflora. When these isolated bifidobacteria were administered on mice, fecal harmful enzymes were also inhibited. Among tested bifidobacteria, B. breve K-110 had the highest inhibitory effect of fecal harmful enzymes.